🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Newly Diagnosed Multiple Myeloma

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma NCT07477587Phase 184 sites📍 Springdale📍 Jacksonville📍 Margate Shanghai Henlius Biotech · Tests: HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant NCT05623020Phase 3180 sites📍 Daphne📍 Daphne📍 Fairhope Pfizer · Tests: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) NCT07045909Phase 210 sites📍 Badalona📍 Barcelona📍 Madrid PETHEMA Foundation · Tests: Daratumumab, Isatuximab, Bortezomib, Lenalidomide, Cyclophosphamide A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma NCT06497738n/a6 sites📍 Changzhou📍 Nanjing📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea NCT06698887n/a5 sites📍 Hwasun📍 Seoul📍 Seoul Bristol-Myers Squibb · Tests: Idecabtagene vicleucel Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure NCT06142396EARLY Phase 11 site📍 Augusta Augusta University · Tests: Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse NCT06910124Phase 21 site📍 Miami Dickran Kazandjian, MD · Tests: Linvoseltamab, Lenalidomide Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise) NCT07851493n/a1 site📍 Munich Technical University of Munich Horizon Two: HR NDMM (MMRC-100) NCT07053436Phase 212 sites📍 Duarte📍 Atlanta📍 Chicago Multiple Myeloma Research Consortium · Tests: Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma NCT07106736Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: BCMA CAR-T, GPRC5D/CD3 BiTEs Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma NCT06149910n/a1 site📍 Seattle All4Cure · Tests: Multiple Myeloma Pathway, All4Cure Platform, Documentation Pathway A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). NCT07638683Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Teclistamab Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702Phase 41 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone, VRD for first-cycle induction therapy Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients NCT06758375Phase 21 site📍 Monterrey Hospital Universitario Dr. Jose E. Gonzalez · Tests: Low-dose teclistamab Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients NCT06682156n/a1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Carfilzomib A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma NCT05552222Phase 3270 sites📍 Gilbert📍 Tucson📍 Clovis Janssen Research & Development, LLC · Tests: Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma NCT07891923Phase 22 sites📍 Navi Mumbai📍 Navi Mumbai Tata Memorial Centre · Tests: Daratumumab (Intravenously), Bortezomib (BTZ), Len (lenalidomide), Dexamethasone KPD Consolidation After ASCT in NDMM Patients NCT06879379Phase 2, Phase 33 sites📍 Beijing📍 Beijing📍 Shanghai Peking University People's Hospital · Tests: KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma NCT06158269Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: DVRd Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT NCT07764978Phase 3124 sites📍 Gilbert📍 Phoenix📍 Tucson AstraZeneca · Tests: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment NCT07585760Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CM336 Plus Isatuximab Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma NCT05145400Phase 25 sites📍 Chapel Hill📍 Charlotte📍 Durham UNC Lineberger Comprehensive Cancer Center · Tests: Isatuximab, Lenalidomide, Dexamethasone BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma NCT06793449Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: anti-BCMA CAR-T, ASCT Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level NCT07649525Phase 35 sites📍 Bristol📍 Eastbourne📍 Leeds University of Leeds · Tests: Daratumumab, Lenalidomide, Dexamethasone, Teclistamab, Talquetamab 18F-Fluciclovine PET/CT in Multiple Myeloma NCT06103838Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: 18F-fluciclovine injection, 18F-FDG PET/CT Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma NCT06974786Phase 211 sites📍 Birmingham📍 Denver📍 Iowa City SCRI Development Innovations, LLC · Tests: Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma NCT07106710Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Autologous Hematopoietic Stem Cell Transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) NCT06187441Phase 338 sites📍 's-Hertogenbosch📍 Almere Stad📍 Amersfoort Stichting Hemato-Oncologie voor Volwassenen Nederland · Tests: Daratumumab Injection, Dexamethasone, Lenalidomide capsule A Dietary Study for People With Multiple Myeloma NCT07226609NA7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: nutrition counseling and coaching, dietary guidelines, research dietitian visit, Questionnaires, Frozen pre-prepared me… Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients NCT05665140Phase 2, Phase 36 sites📍 Berlin📍 Bielefeld📍 Hamburg University Hopsital Schleswig Holstein Campus Lübeck · Tests: Isatuximab, Lenalidomide, Bortezomib, Dexamethasone, autologous stem cell transplant
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy